<DOC>
	<DOCNO>NCT02429375</DOCNO>
	<brief_summary>The purpose study find safe effective treatment new combination drug , mocetinostat brentuximab vedotin , treat cancer . There 2 part trial : phase I part phase II part . Brentuximab vedotin approve U.S. Food Drug Administration ( FDA ) give patient Hodgkin Lymphoma . Mocetinostat experimental drug give patient Hodgkin lymphoma another clinical trial . When give alone , mocetinostat cause lymphoma shrink 1 4 patient Hodgkin lymphoma . This first study give mocetinostat brentuximab vedotin together .</brief_summary>
	<brief_title>Mocetinostat ( MGCD0103 ) Plus Brentuximab Vedotin ( SGN-35 ) Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patients must histologically confirm CD30 positive relapse refractory Hodgkin lymphoma Measurable disease , define International Harmonization Project.14 Patients must fail autologous stem cell transplant least 2 prior cytotoxic regimen Hodgkin lymphoma . Patients fail 1 prior cytotoxic regimen Hodgkin lymphoma permit enroll long eligible autologous stem cell transplant . Age ≥18 ECOG performance status ≤2 ( Karnofsky ≥60 % ) Patients must normal organ marrow function define : absolute neutrophil count ≥1,000/mcL platelets ≥75,000/mcL total bilirubin within normal institutional limit &lt; 3x upper limit normal patient Gilbert 's disease AST ( SGOT ) /ALT ( SGPT ) ≤2.5 × institutional upper limit normal Creatinine ≤1.5 x institutional upper limit normal OR creatinine clearance ≥40 mL/min/1.73 m2 patient creatinine level institutional normal . QTc ≤ 500 m The effect mocetinostat brentuximab vedotin develop human fetus potentially harmful . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant partner participate study , inform treat physician immediately . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion mocetinostat brentuximab vedotin administration . Patients know HIV infection must CD4 count great 200 . Presence small ( great size ) pericardial effusion ; definition pericardial effusion echocardiographic assessment . Patients chemotherapy radiotherapy within 3 week prior enter study Patients recover adverse event due agent administer 3 week earlier . Patients receive investigational agent . Patients known cerebral meningeal involvement lymphoma exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . History allergic reaction attribute compound similar chemical biologic composition mocetinostat brentuximab vedotin . Uncontrolled intercurrent illness include , limited , ongoing active infection , uncontrolled diabetes , clinically significant pneumonitis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Women pregnant breastfeed Previous primary progression grade 3 toxicity treatment brentuximab vedotin Systemic steroid allow long tapered equivalent 20mg prednisone daily less start cycle 2 . Platelet pack red blood cell transfusion within 14 day pretreatment evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mocetinostat ( MGCD0103 )</keyword>
	<keyword>Brentuximab Vedotin ( SGN-35 )</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>